The effect of Agalsidase-Beta Therapy on left ventricular structure and function in Patients with Fabry Disease: a prospective echocardiographic study

被引：0
|
作者：
Lubanda, J. -C. [1 ]
Palecek, T. [1 ]
Kuchynka, P. [1 ]
Karetova, D. [1 ]
Bultas, J. [1 ]
Linhart, A. [1 ]
机构：
[1] Charles Univ Prague, Fac Med 1, Dept Internal Med 2, Prague, Czech Republic
来源：
EUROPEAN HEART JOURNAL | 2007年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：476 / 477
页数：2
相关论文
共 50 条
  • [1] Agalsidase-beta therapy for advanced Fabry disease - A randomized trial
    Banikazemi, Maryam
    Bultas, Jan
    Waldek, Stephen
    Wilcox, William R.
    Whitley, Chester B.
    McDonald, Marie
    Finkel, Richard
    Packman, Seymour
    Bichet, Daniel G.
    Warnock, David G.
    Desnick, Robert J.
    ANNALS OF INTERNAL MEDICINE, 2007, 146 (02) : 77 - 86
  • [2] Fabry disease in children: agalsidase-beta enzyme replacement therapy
    Borgwardt, L.
    Feldt-Rasmussen, U.
    Rasmussen, A. K.
    Ballegaard, M.
    Lund, A. Meldgaard
    CLINICAL GENETICS, 2013, 83 (05) : 432 - 438
  • [3] Dual therapy with migalastat and agalsidase-beta in a patient with Fabry disease with progressing hypertrophic cardiomyopathy
    Stauffer, Chanan
    Balwani, Manisha
    Desnick, Robert J.
    Fierro, Luca
    Ganesh, Jaya
    MOLECULAR GENETICS AND METABOLISM, 2021, 132 (02) : S103 - S103
  • [4] EFFECTS OF SWITCH THERAPY WITH AGALSIDASE-ALFA IN PATIENTS WITH ANDERSON-FABRY DISEASE (AFD) PREVIOUSLY TREATED WITH AGALSIDASE-BETA: A PROSPECTIVE CARDIAC MAGNETIC RESONANCE IMAGING STUDY
    Russo, Roberta
    Pisani, Antonio
    Messalli, Giancarlo
    Imbriaco, Massimo
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 : 323 - 324
  • [5] Effect of changing therapy from agalsidase beta to agalsidase alfa in patients with Fabry disease
    West, M
    Lemoine, K
    ACTA PAEDIATRICA, 2006, 95 : 136 - 136
  • [6] Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy
    Warnock, David G.
    Thomas, Christie P.
    Vujkovac, Bojan
    Campbell, Ruth C.
    Charrow, Joel
    Laney, Dawn A.
    Jackson, Leslie L.
    Wilcox, William R.
    Wanner, Christoph
    JOURNAL OF MEDICAL GENETICS, 2015, 52 (12) : 860 - U91
  • [7] Anti-proteinuric therapy and Fabry nephropathy; factors associated with preserved kidney function during agalsidase-beta therapy
    Warnock, David G.
    Thomas, Christie P.
    Vujkovac, Bojan
    Campbell, Ruth C.
    Charrow, Joel
    Laney, Dawn A.
    Jackson, Leslie L.
    Wilcox, William R.
    Wanner, Christoph
    MOLECULAR GENETICS AND METABOLISM, 2016, 117 (02) : S120 - S120
  • [8] Prospective Results of Switching Enzyme Replacement Therapy from Agalsidase beta to Agalsidase alfa in the Canadian Fabry Disease Initiative Study
    West, Michael
    Bichet, Daniel
    Casey, Robin
    Clarke, Joe
    Sirrs, Sandra
    Flowerdew, Gordon
    LeMoine, Kaye
    MOLECULAR GENETICS AND METABOLISM, 2012, 105 (02) : S64 - S65
  • [9] Utilization of intravenous methylprednisolone to reduce neutralizing agalsidase-beta antibodies in two male pediatric Fabry disease patients
    Woolgar, Kara
    Knoll, Jasmine
    MOLECULAR GENETICS AND METABOLISM, 2024, 141 (02)
  • [10] Agalsidase alfa reduces cardiac mass in patients with Fabry disease with left ventricular hypertrophy: results of a centralized, blinded echocardiographic assessment
    Kampmann, C.
    Linhart, A.
    Schiffmann, R.
    Devereux, R.
    ACTA PAEDIATRICA, 2008, 97 : 108 - 108
12345